Elsevier

Genetics in Medicine

Volume 12, Issue 11, November 2010, Pages 713-720
Genetics in Medicine

Article
Therapeutic goals in the treatment of Fabry disease

https://doi.org/10.1097/GIM.0b013e3181f6e676Get rights and content
Under an Elsevier user license
open archive

Abstract

Purpose

Fabry disease is a progressive multiorgan, multisystem disorder that is caused by a deficiency in the lysosomal enzyme α-galactosidase A. Serious renal, cardiac, and cerebrovascular involvement are responsible for much of the morbidity and premature mortality associated with Fabry disease, and neuropathic pain, gastrointestinal problems, and hypohidrosis negatively affect quality of life of patients with Fabry disease. Fabry disease is X-linked, but women are often symptomatic and may be as severely affected as men.

Methods

We propose a series of therapeutic and symptomatic goals for use in setting the expectations of enzyme replacement therapy and for assessing the response to enzyme replacement therapy in the treatment of Fabry disease.

Results

Enzyme replacement therapy has been available since 2001 and has been associated with benefit in clinical trials, including stabilization of kidney function, improvement of cardiac structure and function, reduction in severity of neuropathic pain, and improvement in gastrointestinal involvement.

Conclusions

The presentation of these therapeutic goals will aid in the evaluation of response to enzyme replacement therapy and be useful in establishing an overall management plan for individual patients.

Keywords

Fabry disease
enzyme replacement therapy
lysosomal storage disease
treatment goals
agalsidase alfa
agalsidase beta

Cited by (0)